FDA OKs Abemaciclib for ER+, HER2- Breast Cancer [News in Brief]

CDK4/6 inhibitor is the third drug in its class to earn approval over the last 2.5 years.

from Cancer via ola Kala on Inoreader http://ift.tt/2y0Chry
via IFTTT